VEGFA and metastatic neoplasm: The subsequent approval of cytokines [interferon (IFN) and interleukin (IL)-2 (3)] and tyrosine kinase inhibitors (TKIs) led to an advantage in survival in patients with metastatic disease (4–7) [>26 months using vascular endothelial growth factor (VEGF) inhibitors (8)].